Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo. Try Elite Free for 7 Days
Login Sign up free
Home Screener Maps Charts News Groups Insider Futures Forex Crypto Portfolio Calendar
Pricing

New upgrade:   Journal your trades with more detail

Read How
Market News Market Pulse Stocks News ETF News Crypto News

Skye Bioscience, Inc.

Contributing Author

Recent Articles by Skye Bioscience, Inc.

Aug-14
Skye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in Financings SKYE -7.30% GlobeNewswire
May-20
Skye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1 SKYE +6.04% GlobeNewswire
May-12
UPDATE - Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update SKYE -7.56% GlobeNewswire
May-11
Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update SKYE GlobeNewswire
Apr-07
Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit SKYE GlobeNewswire
Apr-02
Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development SKYE GlobeNewswire
Mar-10
Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update SKYE +10.33% SKYE -9.70% GlobeNewswire
Mar-05
Skye Bioscience to Announce 2025 Financial Results and Business Update on March 10, 2026 SKYE GlobeNewswire
Feb-02
Skye Reports Positive CBeyond Phase 2a Extension Interim Study Results for Nimacimab in Combination With Semaglutide SKYE -7.92% GlobeNewswire
Jan-29
Skye Bioscience Highlights Attributes of its Peripherally-restricted CB1 Inhibitor Antibody at Keystone Obesity Conference SKYE GlobeNewswire
Jan-21
Skye Bioscience to Present Poster at Keystone Obesity Conference SKYE GlobeNewswire
Jan-12
Skye Provides 2026 Corporate Outlook SKYE GlobeNewswire
Jan-05
Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE for Obesity SKYE GlobeNewswire
Nov-10
Skye Bioscience Reports Third Quarter 2025 Financial Results and Business Update SKYE -7.19% GlobeNewswire
Nov-05
Skye Bioscience Late-Breaking Oral Abstract at ObesityWeek 2025 to Highlight Improvement in Rebound Weight Gain SKYE +6.34% GlobeNewswire
Nov-05
Skye Bioscience to Announce Third Quarter 2025 Financial Results and Business Update on November 10, 2025 SKYE +6.34% GlobeNewswire
Oct-06
Skye Bioscience Reports Topline CBeyond Phase 2a Data from Nimacimab Monotherapy and Combination Clinical Trial SKYE -60.00% GlobeNewswire
Sep-19
Skye Presents Phase 1b Data for its Peripheral CB1-inhibiting Antibody, Nimacimab, at European Association for the Study of Diabetes (EASD) Annual Meeting SKYE GlobeNewswire
Sep-04
Skye's CB1 Inhibitor, Nimacimab, Demonstrates Superior Weight Loss and Differentiated Mechanisms from Monlunabant, and Continues to Show Enhanced Combination with Tirzepatide with Durable Post-Treatment Weight Maintenance in DIO Model SKYE +11.61% GlobeNewswire
Sep-02
Skye Completes 26-week Treatment Phase in Phase 2a CBeyond Study SKYE GlobeNewswire
Aug-27
Skye Bioscience to Host Virtual KOL Event and Provide Perspectives on Upcoming CBeyond Phase 2a Topline Clinical Data Readout SKYE GlobeNewswire
Aug-21
Skye Bioscience to Participate in Upcoming Investment and Medical Conferences SKYE GlobeNewswire
Aug-07
Skye Bioscience Reports Second Quarter 2025 Financial Results and Business Update SKYE -8.74% GlobeNewswire
Jul-30
Skye Bioscience to Announce Second Quarter 2025 Financial Results and Business Update on August 7, 2025 SKYE GlobeNewswire
Jun-23
Skye Bioscience Shares Nimacimab "Anatomy of Progress" Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes Association's 85th Scientific Sessions SKYE +32.87% GlobeNewswire
Jun-17
Skye Bioscience to Present Expanded Preclinical CB1 Antibody Data at the American Diabetes Association's 85th Scientific Sessions SKYE GlobeNewswire
May-22
Skye Bioscience to Participate in Upcoming Investment Conferences SKYE -6.33% GlobeNewswire
May-19
Skye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate Nimacimab SKYE +14.97% GlobeNewswire
May-13
Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) SKYE -5.37% GlobeNewswire
May-13
Skye Bioscience Clinical Model Demonstrating Necessity of Peripheral CB1 Inhibition for Weight Loss Presented at European Congress on Obesity SKYE -5.37% GlobeNewswire
May-08
Skye Bioscience Reports First Quarter 2025 Results and Highlights Nimacimab Differentiation in Obesity SKYE GlobeNewswire
May-07
Skye Bioscience to Announce 2025 First Quarter Financial Results on May 8th, 2025 SKYE GlobeNewswire
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 1 minute for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)